We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+12.98%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$52.8B
AUM Growth
+$12.4B
(+31%)
Cap. Flow
+$6.6B
Cap. Flow
% of AUM
12.49%
Top 10 Holdings %
Top 10 Hldgs %
10.83%
Holding
4,679
New
953
Increased
1,510
Reduced
1,399
Closed
740
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$763M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$336M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$246M |
| 4 |
Apple
AAPL
|
+$203M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$139M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$158M |
| 2 |
Sherwin-Williams
SHW
|
+$155M |
| 3 |
Goldman Sachs
GS
|
+$139M |
| 4 |
Bank of America
BAC
|
+$127M |
| 5 |
Royal Caribbean
RCL
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.3% |
| 2 | Consumer Discretionary | 7.9% |
| 3 | Healthcare | 4.86% |
| 4 | Financials | 4.75% |
| 5 | Industrials | 3.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
THRX
3651
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $169K | ﹤0.01% |
41,708
+22,055
| +112% | +$67.3K |
|
|
GORV
3652
DELISTED
Lazydays
GORV
| $169K | ﹤0.01% |
+798
| New | +$166K |
|
|
ATYR
3653
aTyr Pharma
ATYR
$46.4M
| $168K | ﹤0.01% |
119,450
-20,540
| -15% | -$26.3K |
|
3654
BioXcel Therapeutics
BTAI
$26.2M
| $168K | ﹤0.01% |
+3,568
| New | +$198K |
|
|
TGNA
3655
CALL
DELISTED
TEGNA Inc
TGNA
| $167K | ﹤0.01% |
10,900
-4,100
| -27% | -$61.5K |
|
3656
Carlyle Secured Lending
CGBD
$698M
| $167K | ﹤0.01% |
+11,135
| New | +$162K |
|
3657
CALL
Innoviz Technologies
INVZ
$135M
| $165K | ﹤0.01% |
+65,300
| New | +$125K |
|
|
WOW
3658
DELISTED
WideOpenWest
WOW
| $163K | ﹤0.01% |
+40,153
| New | +$216K |
|
3659
Wolverine World Wide
WWW
$1.54B
| $161K | ﹤0.01% |
18,059
+745
| +4% | +$6.33K |
|
3660
Paysafe
PSFE
$407M
| $160K | ﹤0.01% |
+12,496
| New | +$138K |
|
3661
Seres Therapeutics
MCRB
$48M
| $160K | ﹤0.01% |
+5,700
| New | +$150K |
|
|
OXLC
3662
Oxford Lane Capital
OXLC
$830M
| $159K | ﹤0.01% |
6,428
-4,483
| -41% | -$110K |
|
3663
Rigetti Computing
RGTI
$4.7B
| $158K | ﹤0.01% |
+160,707
| New | +$183K |
|
|
CTLP
3664
DELISTED
Cantaloupe
CTLP
| $158K | ﹤0.01% |
+21,309
| New | +$147K |
|
3665
TransAlta
TAC
$4.34B
| $157K | ﹤0.01% |
+18,900
| New | +$153K |
|
3666
Tronox
TROX
$995M
| $156K | ﹤0.01% |
11,047
+734
| +7% | +$9.01K |
|
3667
CoreCivic
CXW
$3.1B
| $155K | ﹤0.01% |
+10,636
| New | +$141K |
|
3668
CALL
Stem
STEM
$49.2M
| $154K | ﹤0.01% |
1,990
-5
| -0.3% | -$345 |
|
3669
Kearny Financial
KRNY
$592M
| $152K | ﹤0.01% |
16,961
+3,019
| +22% | +$23.4K |
|
|
EGRX
3670
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $151K | ﹤0.01% |
28,960
+18,075
| +166% | +$178K |
|
3671
Zevra Therapeutics
ZVRA
$563M
| $151K | ﹤0.01% |
23,108
+3,930
| +20% | +$18.4K |
|
3672
CALL
PetMed Express
PETS
$42.5M
| $151K | ﹤0.01% |
+20,000
| New | +$164K |
|
3673
Opendoor
OPEN
$3.69B
| $150K | ﹤0.01% |
34,665
-146,554
| -81% | -$409K |
|
|
MAGN
3674
Magnera Corp
MAGN
$488M
| $150K | ﹤0.01% |
5,952
+2,159
| +57% | +$45.5K |
|
3675
Replimune Group
REPL
$814M
| $149K | ﹤0.01% |
+17,716
| New | +$205K |
|
Similar funds
Squarepoint's Q4 2023 Portfolio in Review
As of Q4 2023, Squarepoint held 4,679 positions worth $52.8B, up 31% from $40.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Squarepoint deployed $6.6B of net new capital in Q4 2023, opening 953 new positions and adding to 1,510 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 11% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Intuit, an estimated $158M trimmed.
- Squarepoint's largest Q4 2023 buy was iShares Core S&P 500 ETF: 550,000 shares worth $263M.
- Squarepoint added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $763M increase.
- Squarepoint's biggest Q4 2023 reduction was Intuit, cutting an estimated $158M.
- Squarepoint fully exited State Street SPDR S&P MIDCAP 400 ETF Trust in Q4 2023, selling an estimated $97.9M.
- Squarepoint's ten largest holdings make up 11% of its $52.8B portfolio in Q4 2023.
- Squarepoint opened 953 new positions and closed 740 in Q4 2023.
- Squarepoint's portfolio value rose 31% quarter-over-quarter to $52.8B.
Based on Squarepoint's 13F filing for Q4 2023, filed 14 Feb 2024.